ORIGINAL ARTICLE
The importance of IDH1, ATRX and WT-1 mutations in glioblastoma
1
Pathology Department, Pamukkale University Faculty of Medicine, Denizli, Turkey
2
Radiation Oncology Department, Pamukkale University Faculty of Medicine, Denizli, Turkey
3
Medical Oncology Department, Pamukkale University Faculty of Medicine, Denizli, Turkey
4
Brain Surgery Department, Pamukkale University Faculty of Medicine, Denizli, Turkey
Submission date: 2019-07-28
Final revision date: 2020-01-18
Acceptance date: 2020-02-03
Publication date: 2020-07-21
Pol J Pathol 2020;71(2):127-137
KEYWORDS
TOPICS
ABSTRACT
Numerous genetic pathways associated with glioblastoma development have been identified. In this study, we investigated the prognostic significance of IDH1 and ATRX mutations and WT-1 and p53 expression in glioblastomas and that of surgical methods, radiotherapy and chemotherapy. 83 patients with glioblastomas were retrospectively evaluated. Immunohistochemical analysis was performed for IDH1, ATRX and WT-1 expression. Tumour cells were positive for IDH1 in 9.6% of the patients. In 4.8% of the patients, loss of ATRX expression was observed in tumour cells; 86.7% of the patients were WT-1 positive, and 12.05% of the patients were p53 positive. No statistically significant difference was found in the progression-free and overall survival according to IDH1, ATRX, WT-1 and p53 expression. There was a statistically significant difference in the progression-free and overall survival according to the radiotherapy status. There was a statistically significant difference in the overall survival according to the chemotherapy status. There was no statistically significant difference in the progression-free and overall survival according to the surgical method. IDH1 and ATRX mutations, p53 overexpression and WT-1 expression alone did not have a significant effect on the prognosis of patients with glioblastoma; however, radiotherapy and chemotherapy had a positive effect on survival.
REFERENCES (47)
1.
Ohgaki H, Kleihues P. Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. J Neuropathol Exp Neurol 2005; 64: 479-489.
2.
Stupp R, Hegi ME, Mason WP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009; 10: 459-466.
3.
Masui K, Cloughesy TF, Mischel PS. Review: molecular pathology in adult high-grade gliomas: from molecular diagnostics to target therapies. Neuropathol Appl Neurobiol 2012; 38: 271-291.
4.
Aldape K, Zadeh G, Mansouri S, et al. Glioblastoma: pathology, molecular mechanisms and markers. Acta Neuropathol 2015; 129: 829-848.
5.
Parsons DW, Jones S, Zhang X, et al. An integrated genomic analysis of human glioblastoma multiforme. Science 2008; 321: 1807-1812.
6.
Watanabe T, Nobusawa S, Kleihues P, et al. IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. Am J Pathol 2009; 174: 1149-1153.
7.
Louis DN, Perry A, Reifenberger G, et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol 2016; 131: 803-820.
8.
Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med 2009; 360: 765-773.
9.
Schwartzentruber J, Korshunov A, Liu XY, et al. Driver mutations in histone H3.3 and chromatin remodelling genes in pediatric glioblastoma. Nature 2012; 482: 226-231.
10.
Jiao Y, Killela PJ, Reitman ZJ, et al. Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas. Oncotarget 2012; 3: 709-722.
11.
Chaurasia A, Park SH, Seo JW, et al. Immunohistochemical analysis of ATRX, IDH1 and p53 in glioblastoma and their correlations with patient survival. J Korean Med Sci 2016; 31: 1208-1214.
12.
Cai J, Zhang C, Zhang W, et al. ATRX, IDH1-R132H and Ki-67 immunohistochemistry as a classification scheme for astrocytic tumors. Oncoscience 2016; 3: 7-8.
13.
Pritchard-Jones K. The Wilms tumour gene, WT-1, in normal and abnormal nephrogenesis. Pediatr Nephrol 1999; 13: 620-625.
14.
Hashiba T, Izumoto S, Kagawa N, et al. Expression of WT1 protein and correlation with cellular proliferation in glial tumors. Neurol Med Chir 2007; 47: 165-170.
15.
Oji Y, Suzuki T, Nakano Y, et al. Overexpression of the Wilms’ tumor gene WT1 in primary astrocytic tumors. Cancer Sci 2004; 95: 822-827.
16.
Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008; 455: 1061-1068.
17.
Ohgaki H, Kleihues P. Genetic pathways to primary and secondary glioblastoma. Am J Pathol 2007; 170: 1445-1453.
18.
Ogura R, Tsukamoto Y, Natsumeda M, et al. Immunohistochemical profiles of IDH-1, MGMT and P53: Practical significance for prognostication of patients with diffuse gliomas. Neuropathology 2015; 35: 324-335.
19.
Wiestler B, Capper D, Holland-Letz T, et al. ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumours with better prognosis. Acta Neuropathol 2013; 126: 443-451.
21.
Lee KS, Choe G, Nam KH, et al. Immunohistochemical classification of primary and secondary glioblastomas. Korean J Pathol 2013; 47: 541-548.
22.
Capper D, Weissert S, Balss J, et al. Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors. Brain Pathology 2010; 20: 245-254.
23.
Popova SN, Bergqvist M, Dimberg A, et al. Subtyping of gliomas of various WHO grades by the application of immunohistochemistry. Histopathology 2014; 64: 365-379.
24.
Pekmezci M, Rice T, Molinaro AM, et al. Adult infiltrating gliomas with WHO 2016 integrated diagnosis: additional prognostic roles of ATRX and TERT. Acta Neuropathol 2017; 133: 1001-1016.
25.
Hartmann C, Hentschel B, Wick W, et al. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas. Acta Neuropathologica 2010; 120: 707-718.
26.
Kim YH, Nobusawa S, Mittelbronn M, et al. Molecular classification of low-grade diffuse gliomas. Am J Pathol 2010; 177: 2708-2714.
27.
Chen JR, Yao Y, Xu HZ, et al. Isocitrate dehydrogenase (IDH)1/2 mutations as prognostic markers in patients with glioblastomas. Medicine (Baltimore) 2016; 95: e2583.
28.
Combs SE, Rieken S, Wick W, et al. Prognostic significance of IDH1 and MGMT in patients with glioblastoma: One step forward, and one step back? Radiat Oncol 2011; 6: 115.
29.
Paldor I, Drummond KJ, Kaye AH. IDH1 mutation may not be prognostically favorable in glioblastoma when controlled for tumor location. J Clin Neurosci 2016; 34: 117-120.
30.
Kannan K, Inagaki A, Silber J, et al. Whole-exome sequencing identifies ATRX mutation as a key molecular determinant in lower-grade glioma. Oncotarget 2012; 3: 1194-1203.
31.
Liu XY, Gerges N, Korshunov A, et al. Frequent ATRX mutations and loss of expression in adult diffuse astrocytic tumours carrying IDH1/IDH2 and TP53 mutations. Acta Neuropathol 2012; 124: 615-625.
32.
Reuss DE, Sahm F, Schrimpf D, et al. ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an “integrated” diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma. Acta Neuropathol 2015; 129: 133-146.
33.
Uppar AM, Sugur H, Prabhuraj AR, et al. H3K27M, IDH1 and ATRX expression in pediatric GBM and their clinical and prognostic significance. Childs Nerv Syst 2019; 35: 1537-1545.
34.
Clark AJ, Dos Santos WG, McCready J, et al. Wilms tumor 1 expression in malignant gliomas and correlation of 1 KTS isoforms with p53 status. J Neurosurg 2007; 107: 586-592.
35.
Schittenhelm J, Beschorner R, Simon P, et al. Diagnostic value of WT1 in neuroepithelial tumours. Neuropathol Appl Neurobiol 2009; 35: 69-81.
36.
Rushing EJ, Sandberg GD, Horkayne-Szakaly I. High-grade astrocytomas show increased Nestin and Wilms’s Tumor Gene (WT1) protein expression. Int J Surg Pathol 2010; 18: 255-259.
37.
Schmidt MC, Antweiler S, Urban N, et al. Impact of genotype and morphology on the prognosis of glioblastoma. J Neuropathol Exp Neurol 2002; 61: 321-328.
38.
Bourne TD, Elias WJ, Lopes MB, Mandell JW. WT1 is not a reliable marker to distinguish reactive from neoplastic astrocyte populations in the central nervous system. Brain Pathol 2010; 20: 1090-1095.
39.
Rauscher J, Berchorner R, Gierke M, et al. WT1 expression increases with malignancy and indicates unfavourable outcome in astrocytoma. J Clin Pathol 2014; 67: 556-561.
40.
Schwab DE, Lepski G, Borchers C, et al. Immunohistochemical comparative analysis of GFAP, MAP-2, NOGO-A, OLIG-2 and WT-1 expression in WHO 2016 classified neuroepithelial tumours and their prognostic value. Pathol Res Pract 2018; 214: 15-24.
41.
Camacho-Urkaray E, Santos-Juanes J, Gutiérrez-Corres FB, et al. Establishing cut-off points with clinical relevance for bcl-2, cyclin D1, p16, p21, p27, p53, Sox11 and WT1 expression in glioblastoma – a short report. Cell Oncol 2018; 41: 213-221.
42.
Rauscher J, Beschorner R, Gierke M, et al. WT1 expression increases with malignancy and indicates unfavourable outcome in astrocytoma. J Clin Pathol 2014; 67: 556-561.
43.
Watanabe K, Tachibana O, Sata K, et al. Overexpression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas. Brain Pathol 1996; 6: 217-223.
44.
Simmons ML, Lamborn KR, Takahashi M, et al. Analysis of complex relationships between age, p53, epidermal growth factor receptor, and survival in glioblastoma patients. Cancer Res 2001; 61: 1122-1128.
45.
Smith JS, Tachibana I, Passe SM, et al. PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme. J Natl Cancer Inst 2001; 93: 1246-1256.
46.
Ohgaki H, Dessen P, Jourde B, et al. Genetic pathways to glioblastoma: a population-based study. Cancer Res 2004; 64: 6892-6899.
47.
Montgomery RM, Queiroz LS, Rogerio F. EGFR, p53, IDH1 and MDM2 immunohistochemical analysis in glioblastoma: therapeutic and prognostic correlation. Arq Neuropsiquiatr 2015; 73: 561-568.
Share
RELATED ARTICLE
| eISSN: | 2084-9869 |
| ISSN: | 1233-9687 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
